Most Active Stories
- Bradley Completes 'Grid' Of 4,000-Footers, Every Mountain In Every Month
- Dartmouth Once Again Weighing Value Of Greek Life On Campus
- How Kickstarter Kept A North Country Cafe Open - And Kept It In The Family
- Freezing Rain Causes Treacherous Roadways, Multiple Accidents
- Bill Would Require N.H. Employers To Offer Five Sick Days Per Year
Shots - Health Blog
Mon July 16, 2012
FDA Approves First Drug To Prevent HIV Infection
Originally published on Tue July 17, 2012 2:57 pm
The Food and Drug Administration has given the first OK for a drug to prevent HIV infection.
The daily pill Truvada, made by Gilead Sciences, combines two medicines that inhibit the reproduction of HIV. It's been a mainstay in the treatment of HIV/AIDS for years, and as of today is an approved option for reducing the risk of HIV infection for people at high risk.
The drug was approved for people who test negative for HIV infection. It's supposed to be used in combination with safe-sex practices, such as using a condom, to reduce infection risk. "Truvada alone shouldn't be used to prevent HIV infection," FDA's Dr. Debra Birnkrant said in a media briefing.
People taking Truvada should be tested for HIV infection every three months, so treatment can begin promptly if an infection has occurred.
An outside panel of experts had recommend the agency take the action after concluding that the benefits to healthy people vulnerable to HIV infection outweigh the risks, including such side effects as kidney damage and a dangerous increase in acid in the blood.
About 50,000 people in the U.S. become infected with HIV each year, according to the Centers for Disease Control and Prevention. The majority of new infections are in gay or bisexual men.
Birnkrant said the steady rate of new infections showed that more options are needed to reduce transmission of the virus. "Truvada for pre-exposure prevention represents another effective evidence-based approach," she said.
But the cost for prevention isn't trivial. The annual tab for Truvada ranges from about $11,000 to $14,000.
In an interview with Talk of Nation's Neal Conan in May, the National Institute of Health's Anthony Fauci, said of Truvada, that it's "an important component of the broad tool kits that we do have for prevention."
He acknowledged the risks, such as side effects, and the possibility that some people taking the drug might engage in riskier behavior because they think they're protected.
In response to a question about that from NPR's Richard Knox today, FDA's Birnkrant said studies of Truvada for prevention found an increase in condom use over time — not a drop. (Listen to Knox's story on Monday's All Things Considered for more.)
During the Fauci interview conducted shortly after the expert panel recommended FDA approval of Truvada for prevention, he said, "I agree with the advisory committee strongly that when you balance the benefits of this, making this available, to the risks, ... the benefits far outweigh the risks, although you must take seriously the potential downsides of it and be prudent in your use of this."
ROBERT SIEGEL, HOST:
From NPR News, this is ALL THINGS CONSIDERED. I'm Robert Siegel.
AUDIE CORNISH, HOST:
And I'm Audie Cornish. Today, the Food and Drug Administration approved a pill that can prevent HIV. It's the first medication to do that. Studies show the pill can drastically reduce the risk of infection, but the FDA stresses that people have to take it faithfully every day and keep practicing safe sex.
NPR's Richard Knox explains.
RICHARD KNOX, BYLINE: Scientists call it PREP. That stands for pre-exposure prophylaxis. That just means that people take the pill before they're exposed to the AIDS virus in order to prevent infection with HIV. A number of studies all over the world have shown that it can work. It can cut the risk of infection anywhere from 44 to 90 percent. We'll get back to why there's such a wide range in a minute.
The pill is called Truvada. It's a combination of two antiviral drugs that have been widely used for several years to treat people already infected with HIV. In approving Truvada for PREP, officials say they hope the pill can prevent some of the 50,000 new infections that occur in this country every year, but Dr. Debra Birnkrant of the FDA says it's not clear what the impact will be.
DR. DEBRA BIRNKRANT: I don't think we know exactly how many individuals will be using Truvada for PREP.
KNOX: The FDA is stressing that people taking the pill shouldn't feel they're safe.
BIRNKRANT: Truvada alone should not be used to prevent HIV infection.
KNOX: They should continue to use condoms and limit the number of sexual partners they have. One big worry is whether people taking Truvada will relax other safe sex precautions.
BIRNKRANT: We are concerned about increased risks, however, the trials did not bear that out and the goal is that the health care providers, when they have their extensive conversations with individuals, they will go through key messages.
KNOX: Those messages are only partly about condoms and promiscuity. There are other important issues. Nobody should start taking Truvada for PREP before making sure he or she is not already infected with HIV. That's because this pill by itself is not effective in fighting an infection once it's begun. That requires at least one additional antiviral drug. Without it, the virus may become more difficult to treat.
People taking Truvada for PREP also need to get an HIV test every three months and people with kidney problems or Hepatitis B should not be using Truvada. But the most important message is you've got to take the pill every single day. People who did that in studies had a high level of protection, says Boston AIDS researcher Kenneth Mayer.
KENNETH MAYER: The people assigned to the PREP group who were consistently taking their medication had a benefit of 90 percent that they were that much less likely to become HIV infected compared to people assigned to the placebo group.
KNOX: But studies also showed that most people weren't faithful about taking the pill and, when they didn't, their risk was reduced much less to 75 percent, 44 percent or zero. Mayer says achieving perfect adherence is unrealistic.
MAYER: Nobody thinks that that's necessarily obtainable.
KNOX: So doctors who prescribe PREP need to have frank talks with patients about their ability to stick to the regimen.
MAYER: It's certainly not something that we want to just distribute in the drinking water or just distribute willy-nilly, because people really have to understand the need for a certain regimentation in taking the medication.
KNOX: There's another big unknown. In this country, Truvada costs around $13,000 a year. It's not yet clear how many insurers will pay for that.
Richard Knox, NPR News. Transcript provided by NPR, Copyright NPR.